Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis




Julkaisun tekijätMälkönen Tarja, Nuutinen Pauliina, Hallinen Taru, Soini Erkki, Nissinen Riikka, Wennerstöm Christina, Rantanen Tapio, Hagman Johanna H., Harvima Rauno, Höök-Nikanne Johanna, Ilves Tiina, Lintu Päivi, Malanin Ken, Soramäki Iina, Tasanen Kaisa, Teho Arja, Vähävihu Katja, Itälinna Sari, Leinonen Pekka, Sarajärvi Piia, Huilaja Laura, Pasternack Rafael

KustantajaMedical Journals/Acta D-V

Julkaisuvuosi2022

JournalActa Dermato-Venereologica

Tietokannassa oleva lehden nimiActa Dermato-Venereologica

Artikkelin numeroadv00631

Volyymi102

eISSN1651-2057

DOIhttp://dx.doi.org/10.2340/actadv.v101.910

Verkko-osoitehttps://doi.org/10.2340/actadv.v101.910

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/175034990


Tiivistelmä

Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2023-15-06 at 16:08